Nitric oxide-releasing polysaccharide derivative exhibits 8-log reduction against Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus

Journal of Controlled Release

Volumn 217, Issue , 2015, Pages 228-234

  Pegalajar Jurado, Adoracion ^a   Wold, Kathryn A ^b   Joslin, Jessica M ^a   Neufeld, Bella H ^a   Arabea, Kristin A ^a   Suazo, Lucas A ^b   McDaniel, Stephen L ^a   Bowen, Richard A ^a   Reynolds, Melissa M ^a,b  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b Engineering Research Center and Hydraulics Laboratory   (United States)

Author keywords

8 Log reduction; Bactericidal; Nitric oxide releasing; Polysaccharide

Indexed keywords

BACTERIA; BIOMATERIALS; ESCHERICHIA COLI; HEALTH RISKS; MICROORGANISMS; NITRIC OXIDE; NUTRIENTS; POLYSACCHARIDES;

ANTIBIOTIC-RESISTANT BACTERIA; BACTERICIDAL; DRUG-RESISTANT STRAINS; EXPERIMENTAL CONDITIONS; POLYSACCHARIDE DERIVATIVES; STAPHYLOCOCCUS AUREUS; STERILIZATION PROTOCOLS; WATER SOLUBLE COMPOUNDS;

REDUCTION;

NITRIC OXIDE DONOR; POLYSACCHARIDE; ANTIINFECTIVE AGENT; DEXTRAN; NITRIC OXIDE;

ACINETOBACTER BAUMANNII; ARTICLE; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; CHEMOLUMINESCENCE; ESCHERICHIA COLI; HEALTHCARE ASSOCIATED INFECTION; MICROBIAL ACTIVITY; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STAPHYLOCOCCUS AUREUS; CHEMISTRY; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; DEXTRANS; ESCHERICHIA COLI; NITRIC OXIDE; STAPHYLOCOCCUS AUREUS;

EID: 84942105191     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.09.015     Document Type: Article

References (64)

1. P. Zarb, and et al. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use Euro Surveill. 17 46 2012 1 16
2. S.S. Magill, and et al. Multistate point-prevalence survey of health care-associated infections N. Engl. J. Med. 370 13 2014 1198 1208
3. R.D. Scott The Direct Medical Costs of Healthcare-associated Infections in US Hospitals and the Benefits of Prevention 2009
4. S. Leekha, C.L. Terrell, and R.S. Edson General principles of antimicrobial therapy Mayo Clinic Proceedings 2011 Elsevier
5. K.J. Towner Acinetobacter: an old friend, but a new enemy J. Hosp. Infect. 73 4 2009 355 363
6. H. Giamarellou, A. Antoniadou, and K. Kanellakopoulou Acinetobacter baumannii: a universal threat to public health? Int. J. Antimicrob. Agents 32 2 2008 106 119
7. S.N. Coulter, and et al. Staphylococcus aureus genetic loci impacting growth and survival in multiple infection environments Mol. Microbiol. 30 2 1998 393 404
8. J. Perlroth, and et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature Arch. Intern. Med. 168 8 2008 805 819
9. C.S. Wong, and et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections N. Engl. J. Med. 342 26 2000 1930 1936
10. M. Falagas, I. Bliziotis, and I. Siempos Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies Crit. Care 10 2 2006 R48
11. M.E. Falagas, and P. Kopterides Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature J. Hosp. Infect. 64 1 2006 7 15
12. I.K. Neonakis, D.A. Spandidos, and E. Petinaki Confronting multidrug-resistant Acinetobacter baumannii: a review Int. J. Antimicrob. Agents 37 2 2011 102 109
13. M.L. Moro Health care-associated infections Surg. Infect. 7 supplement 2 2006 s-21 s-23
14. L.P.G. Derde, and et al. Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial Lancet Infect. Dis. 14 1 2014 31 39
15. Organization, W.H. Antimicrobial Resistance: Global Report on Surveillance 2014 World Health Organization
16. I. Chopra, and et al. Treatment of health-care-associated infections caused by gram-negative bacteria: a consensus statement Lancet Infect. Dis. 8 2 2008 133 139
17. D.E. Karageorgopoulos, and M.E. Falagas Current control and treatment of multidrug-resistant Acinetobacter baumannii infections Lancet Infect. Dis. 8 12 2008 751 762
18. D.M. Sievert, and et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010 Infect. Control Hosp. Epidemiol. 34 01 2013 1 14
19. L.M. Baddour, and et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America Circulation 111 23 2005 e394 e434
20. D.J. Diekema, and et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997-1999 Clin. Infect. Dis. 32 Supplement 2 2001 S114 S132
21. R.E.W. Hancock Peptide antibiotics Lancet 349 9049 1997 418 422
22. C. Vreuls, and et al. Prevention of bacterial biofilms by covalent immobilization of peptides onto plasma polymer functionalized substrates J. Mater. Chem. 20 37 2010 8092 8098
23. D. Santoro, and C.W. Maddox Canine antimicrobial peptides are effective against resistant bacteria and yeasts Vet. Dermatol. 25 1 2014 35-+
24. A.K. Marr, W.J. Gooderham, and R.E. Hancock Antibacterial peptides for therapeutic use: obstacles and realistic outlook Curr. Opin. Pharmacol. 6 5 2006 468 472
25. A.W. Carpenter, and M.H. Schoenfisch Nitric oxide release: part II. Therapeutic applications Chem. Soc. Rev. 41 10 2012 3742 3752
26. B.J. Privett, and et al. Examination of bacterial resistance to exogenous nitric oxide Nitric Oxide Biol. Chem. 26 3 2012 169 173
27. M.C. Jen, and et al. Polymer-based nitric oxide therapies: recent insights for biomedical applications Adv. Funct. Mater. 22 2 2012 239 260
28. D.A. Riccio, and M.H. Schoenfisch Nitric oxide release: part I. Macromolecular scaffolds Chem. Soc. Rev. 41 10 2012 3731 3741
29. J.F. Quinn, M.R. Whittaker, and T.P. Davis Delivering nitric oxide with nanoparticles J. Control. Release 205 2015 190 205
30. Y. Feng, and et al. Nitric oxide release from polycarbonate-urethane films containing copper(ii) complexes J. Control. Release 152 Supplement 1 2011 e202 e204
31. M.L. Jones, and et al. A novel nitric oxide producing probiotic patch and its antimicrobial efficacy: preparation and in vitro analysis Appl. Microbiol. Biotechnol. 87 2 2010 509 516
32. B.J. Nablo, T.Y. Chen, and M.H. Schoenfisch Sol-gel derived nitric-oxide releasing materials that reduce bacterial adhesion J. Am. Chem. Soc. 123 39 2001 9712 9713
33. E.M. Hetrick, and et al. Bactericidal efficacy of nitric oxide-releasing silica nanoparticles ACS Nano 2 2 2008 235 246
34. D.A. Riccio, and et al. Nitric oxide-releasing S-nitrosothiol-modified xerogels Biomaterials 30 27 2009 4494 4502
35. A.W. Carpenter, and et al. Influence of scaffold size on bactericidal activity of nitric oxide-releasing silica nanoparticles ACS Nano 5 9 2011 7235 7244
36. N. Naghavi, and et al. Nitric oxide donors for cardiovascular implant applications Small 9 1 2013 22 35
37. B. Sun, and et al. Nitric oxide-releasing dendrimers as antibacterial agents Biomacromolecules 13 10 2012 3343 3354
38. Y. Lu, and et al. Nitric oxide-releasing amphiphilic poly(amidoamine) (PAMAM) dendrimers as antibacterial agents Biomacromolecules 14 10 2013 3589 3598
39. Y. Lu, and et al. Shape- and nitric oxide flux-dependent bactericidal activity of nitric oxide-releasing silica nanorods Small 9 12 2013 2189 2198
40. W.L. Storm, and et al. Superhydrophobic nitric oxide-releasing xerogels Acta Biomater. 10 8 2014 3442 3448
41. M. Neidrauer, and et al. Antimicrobial efficacy and wound-healing property of a topical ointment containing nitric-oxide-loaded zeolites J. Med. Microbiol. 63 2014 203 209
42. J.M. Joslin, V.B. Damodaran, and M.M. Reynolds Selective nitrosation of modified dextran polymers RSC Adv. 3 35 2013 15035 15043
43. V.B. Damodaran, and et al. Enzymatically degradable nitric oxide releasing S-nitrosated dextran thiomers for biomedical applications J. Mater. Chem. 22 43 2012 23038 23048
44. M.M. Reynolds, and et al. Nitric oxide releasing polyurethanes with covalently linked diazeniumdiolated secondary amines Biomacromolecules 7 3 2006 987 994
45. A. Pegalajar-Jurado, and et al. Antibacterial activity studies of plasma polymerised cineole films J. Mater. Chem. B 2 2014 4993 5002
46. A.L. Barry, and et al. Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline 1999 National Committee for Clinical Laboratory Standards
47. K. Francois, and et al. Environmental factors influencing the relationship between optical density and cell count for Listeria monocytogenes J. Appl. Microbiol. 99 6 2005 1503 1515
48. ASTM, D. Standard Practice for Determining Microbial Colony Counts from Water Analyzed by Plating Methods 2012
49. S. Sutton Accuracy of plate counts J. Validation Tecnhol. 17 2011 42 46
50. S. Sutton The limitations of CFU: compliance to CGMP requires good science J. GXP Compliance 16 1 2012 74
51. Univeristy, M.S. The Log Reduction (LR) Measure of Disinfectant Efficacy 2010
52. D.L. Slomberg, and et al. Role of size and shape on biofilm eradication for nitric oxide-releasing silica nanoparticles ACS Appl. Mater. Interfaces 5 19 2013 9322 9329
53. A.W. Carpenter, and et al. Dual action antimicrobials: nitric oxide release from quaternary ammonium-functionalized silica nanoparticles Biomacromolecules 13 10 2012 3334 3342
54. J.L. Harding, and M.M. Reynods Accurate nitric oxide measurements from donors in cell media: identification of scavenging agents Anal. Chem. 86 4 2014 2025 2032
55. K.S. Hong, and J.S. Kim Rifaximin for the treatment of acute infectious diarrhea Ther. Adv. Gastroenterol. 4 4 2011 227 235
56. M.J. Hajipour, and et al. Antibacterial properties of nanoparticles Trends Biotechnol. 30 10 2012 499 511
57. M. Marini, and et al. Preparation and antibacterial activity of hybrid materials containing quaternary ammonium salts via sol-gel process Eur. Polym. J. 43 8 2007 3621 3628
58. J.R. Morones, and et al. The bactericidal effect of silver nanoparticles Nanotechnology 16 10 2005 2346
59. L. Dijkshoorn, A. Nemec, and H. Seifert An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii Nat. Rev. Microbiol. 5 12 2007 939 951
60. A.Y. Peleg, H. Seifert, and D.L. Paterson Acinetobacter baumannii: emergence of a successful pathogen Clin. Microbiol. Rev. 21 3 2008 538 582
61. F. Martinez-Gutierrez, and et al. Synthesis, characterization, and evaluation of antimicrobial and cytotoxic effect of silver and titanium nanoparticles Nanomed. Nanotechnol. Biol. Med. 6 5 2010 681 688
62. E.S.R. Darley, and A.P. MacGowan Antibiotic treatment of gram-positive bone and joint infections J. Antimicrob. Chemother. 53 6 2004 928 935
63. I. Sulemankhil, and et al. Prevention and treatment of virulent bacterial biofilms with an enzymatic nitric oxide-releasing dressing Antimicrob. Agents Chemother. 56 12 2012 6095 6103
64. J. May, and et al. Time-kill studies of tea tree oils on clinical isolates J. Antimicrob. Chemother. 45 5 2000 639 643